๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Primary oxalosis: Clinical and biochemical response to high-dose pyridoxine therapy

โœ Scribed by Eric J. Will; Olav L.M. Bijvoet

Book ID
118948073
Publisher
Elsevier Science
Year
1979
Tongue
English
Weight
656 KB
Volume
28
Category
Article
ISSN
1532-8600

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

High-dose cytosine arabinoside: Clinical
High-dose cytosine arabinoside: Clinical response to therapy in acute leukemia
โœ Early, A. P. ;Preisler, H. D. ;Higby, D. J. ;Brecher, M. ;Browman, G. ;McBride, ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 664 KB

High dose cytosine arabinoside (HD-AraC) was evaluated 1) as remission induction therapy for refractory acute leukemia and high risk AML, 2) as augmentation therapy for acute leukemia, and 3) as conditioning therapy prior to allogeneic bone marrow transplantation for acute leukemia. Seven of 10 pati

Functional COMT variant predicts respons
Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease
โœ Eng-King Tan; Sin-Yun Cheah; Stephanie Fook-Chong; Kenneth Yew; V.R. Chandran; S ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 67 KB ๐Ÿ‘ 2 views

Pyridoxal-5-phosphate, the biological active form of pyridoxine, is a cofactor for dopa-decarboxylase (DDC) enzyme. Pyridoxine may augment the conversion of levodopa to dopamine in the periphery and therefore decrease availability of levodopa to the brain. However, this effect can be negated in the